Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice.
Schmid AM, Razim A, Wysmołek M, Kerekes D, Haunstetter M, Kohl P, Brazhnikov G, Geissler N, Thaler M, Krčmářová E, Šindelář M, Weinmayer T, Hrdý J, Schmidt K, Nejsum P, Whitehead B, Palmfeldt J, Schild S, Inić-Kanada A, Wiedermann U, Schabussova I. Schmid AM, et al. Among authors: wiedermann u. Cell Commun Signal. 2023 Oct 20;21(1):297. doi: 10.1186/s12964-023-01329-4. Cell Commun Signal. 2023. PMID: 37864211 Free PMC article.
Correction: Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice.
Schmid AM, Razim A, Wysmołek M, Kerekes D, Haunstetter M, Kohl P, Brazhnikov G, Geissler N, Thaler M, Krčmářová E, Šindelář M, Weinmayer T, Hrdý J, Schmidt K, Nejsum P, Whitehead B, Palmfeldt J, Schild S, Inić-Kanada A, Wiedermann U, Schabussova I. Schmid AM, et al. Among authors: wiedermann u. Cell Commun Signal. 2023 Dec 6;21(1):349. doi: 10.1186/s12964-023-01405-9. Cell Commun Signal. 2023. PMID: 38057928 Free PMC article. No abstract available.
Bacterial extracellular vesicles as intranasal postbiotics: Detailed characterization and interaction with airway cells.
Razim A, Zabłocka A, Schmid A, Thaler M, Černý V, Weinmayer T, Whitehead B, Martens A, Skalska M, Morandi M, Schmidt K, Wysmołek ME, Végvári A, Srutkova D, Schwarzer M, Neuninger L, Nejsum P, Hrdý J, Palmfeldt J, Brucale M, Valle F, Górska S, Wisgrill L, Inic-Kanada A, Wiedermann U, Schabussova I. Razim A, et al. Among authors: wiedermann u. J Extracell Vesicles. 2024 Oct;13(10):e70004. doi: 10.1002/jev2.70004. J Extracell Vesicles. 2024. PMID: 39429019 Free PMC article.
A Biomimetic, Silaffin R5-Based Antigen Delivery Platform.
Reichinger D, Reithofer M, Hohagen M, Drinic M, Tobias J, Wiedermann U, Kleitz F, Jahn-Schmid B, Becker CFW. Reichinger D, et al. Among authors: wiedermann u. Pharmaceutics. 2022 Dec 29;15(1):121. doi: 10.3390/pharmaceutics15010121. Pharmaceutics. 2022. PMID: 36678751 Free PMC article.
Flow Cytometry-Based Measurement of Antibodies Specific for Cell Surface-Expressed Folded SARS-CoV-2 Receptor-Binding Domains.
Sehgal ANA, Safran J, Kratzer B, Gattinger P, Stieger RB, Musiejovsky L, Trapin D, Ettel P, Körmöczi U, Rottal A, Borochova K, Dorofeeva Y, Tulaeva I, Weber M, Grabmeier-Pfistershammer K, Perkmann T, Wiedermann U, Valenta R, Pickl WF. Sehgal ANA, et al. Among authors: wiedermann u. Vaccines (Basel). 2024 Apr 1;12(4):377. doi: 10.3390/vaccines12040377. Vaccines (Basel). 2024. PMID: 38675759 Free PMC article.
Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.
Sieghart D, Hana CA, Dürrschmid C, Heinz LX, Haslacher H, Zlesak M, Piccini G, Manenti A, Montomoli E, Jorda A, Fedrizzi C, Hasenoehrl T, Zdravkovic A, Anderle K, Wiedermann U, Drapalik S, Steinbrecher H, Bergmann F, Firbas C, Jordakieva G, Wagner B, Leonardi M, Pierleoni G, Ballini M, Benincasa L, Marchi S, Trombetta C, Perkmann T, Crevenna R, Zeitlinger M, Bonelli M, Aletaha D, Radner H. Sieghart D, et al. Among authors: wiedermann u. J Clin Virol. 2024 Aug;173:105661. doi: 10.1016/j.jcv.2024.105661. Epub 2024 Feb 28. J Clin Virol. 2024. PMID: 38503118 Clinical Trial.
The PreS-Based Recombinant Vaccine VVX001 Induces Hepatitis B Virus Neutralizing Antibodies in a Low-Responder to HBsAg-Based HBV Vaccines.
Tulaeva I, Lehmann F, Goldmann N, Dubovets A, Trifonova D, Tulaev M, Cornelius C, Weber M, Focke-Tejkl M, Karaulov A, Henning R, Springer DN, Wiedermann U, Glebe D, Valenta R. Tulaeva I, et al. Among authors: wiedermann u. Vaccines (Basel). 2024 Sep 30;12(10):1123. doi: 10.3390/vaccines12101123. Vaccines (Basel). 2024. PMID: 39460290 Free PMC article.
194 results